Urinary OPN excretion in children with glomerular proteinuria

Advances in Medical Sciences

Volumn 56, Issue 2, 2011, Pages 193-199

  Wasilewska, A ^a   Taranta Janusz, K ^a   Kuroczycka Saniutycz, E ^a   Zoch Zwierz, W ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

nephrotic syndrome; osteopontin; proteinuria

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OSTEOPONTIN; PREDNISONE;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE URINE LEVEL; DISEASE ASSOCIATION; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC NEPHROTIC SYNDROME; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PRESCHOOL CHILD; PROTEIN URINE LEVEL; PROTEINURIA; RELAPSE; REMISSION; SCHOOL CHILD; URINARY EXCRETION;

EID: 84855428024     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-011-0034-y     Document Type: Article

References (29)

1. Rangaswami H, Bulbule A, Kundu G. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2004 Sep; 279(37): 38921-35. (Pubitemid 39296053)
2. Lorenzen J, Shah R, Biser A, Staicu S, Niranjan T, Garcia A, Gruenwald A, Thomas D, Shatat I, Supe K, Woroniecki R, Susztak K. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol. 2008 May; 19(5): 884-90.
3. Wei C, Muller C, Altintas M, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi M, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modifcation of kidney barrier function by the urokinase receptor. Nat Med. 2008 Jan; 14(1): 55-63.
4. Hudkins KL, Giachelli CM, Cui Y, Couser WG, Johnson RJ, Alpers CE. Osteopontin expression in fetal and mature human kidney. J Am Soc Nephrol. 1999 Mar; 10(3): 444-57. (Pubitemid 29117625)
5. Rangaswami H, Bulbule A, Kundu G. JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J Biol Chem. 2005 May; 280(19): 19381-92. (Pubitemid 41379646)
6. Nicholas S, Liu J, Kim J, Ren Y, Collins A, Nguyen L, Hsueh W. Critical role for osteopontin in diabetic nephropathy. Kidney Int. 2010 Apr; 77(7): 588-600.
7. Ophascharoensuk V, Giachelli C, Gordon K, Hughes J, Pichler R, Brown P, Liaw L, Schmidt R, Shankland S, Alpers C, Couser W, Johnson R. Obstructive uropathy in the mouse: role of osteopontin in interstitial fbrosis and apoptosis. Kidney Int. 1999 Aug; 56(2): 571-80. (Pubitemid 29353155)
8. Wolak T, Kim H, Ren Y, Kim J, Vaziri N, Nicholas S. Osteopontin modulates angiotensin II-induced infammation, oxidative stress, and fbrosis of the kidney. Kidney Int. 2009 Jul; 76(1): 32-43.
9. Gang X, Ueki K, Kon S, Maeda M, Naruse T, Nojima Y. Reduced urinary excretion of intact osteopontin in patients with IgA nephropathy. Am J Kidney Dis. 2001 Feb; 37(2): 374-9. (Pubitemid 32116031)
10. Oyama Y, Akuzawa N, Nagai R, Kurabayashi M. PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells. Circ Res. 2002 Feb; 90(3): 348-55. (Pubitemid 34633937)
11. Eddy A, Symons J. Nephrotic syndrome in childhood. Lancet 2003 Aug; 362(9384): 629-39. (Pubitemid 37013306)
12. Heuer J, Breyer M. Osteopontin in diabetic nephropathy: signpost or road? Kidney Int. 2010 Apr; 77(7): 565-6.
13. Shui H, Ka S, Yang S, Lin Y, Lo Y, Chen A. Osteopontin as an injury marker expressing in epithelial hyperplasia lesions helpful in prognosis of focal segmental glomerulosclerosis. Transl Res. 2007 Oct; 150(4): 216-22. (Pubitemid 47444611)
14. Hudkins K, Giachelli C, Eitner F, Couser W, Johnson R, Alpers C. Osteopontin expression in human crescentic glomerulonephritis. Kidney Int. 2000 Jan; 57(1): 105-16. (Pubitemid 30227758)
15. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 2001 Nov; 60(5): 1645-57. (Pubitemid 32999968)
16. Kramer A, Ricardo S, Kelly D, Waanders F, van Goor H, Navis G. Modulation of osteopontin in proteinuria-induced renal interstitial fbrosis. J Pathol. 2005 Dec; 207(4): 483-92. (Pubitemid 43025697)
17. Kikuchi H, Kawachi H, Ito Y, Matsui K, Nosaka H, Saito A, Orikasa M, Arakawa M, Shimizu F. Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infltration in rats but not progressive interstitial fbrosis. Nephrol Dial Transplant. 2000 Jun; 15(6): 799-810. (Pubitemid 30311997)
18. De Bosscher K, Vanden Berghe W, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000 Apr; 97(8): 3919-24. (Pubitemid 30226062)
19. El-Reshaid K, El-Reshaid W, Madda J. Combination of immunosuppressive agents in treatment of steroid-resistant minimal change disease and primary focal segmental glomerulosclerosis. Ren Fail. 2005; 27(5): 523-30. (Pubitemid 41216307)
20. Stokes M, Valeri A, Markowitz G, D'Agati V. Cellular focal segmental glomerulosclerosis: Clinical and pathologic features. Kidney Int. 2006 Nov; 70(10): 1783-92. (Pubitemid 44684810)
21. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2005 Nov; 1(1): 44-54.
22. Thomas D, Franceschini N, Hogan S, Ten Holder S, Jennette C, Falk R, Jennette J. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006 Mar; 69(5): 920-6.
23. Yu X, Nikolic-Paterson D, Mu W, Giachelli C, Atkins R, Johnson R, Lan H. A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 1998 Jan-Feb; 110(1): 50-64. (Pubitemid 28051638)
24. Lan H, Yu X, Yang N, Nikolic-Paterson D, Mu W, Pichler R, Johnson R, Atkins R. De novo glomerular osteopontin expression in rat crescentic glomerulonephritis. Kidney Int. 1998 Jan; 53(1): 136-45. (Pubitemid 28066913)
25. Alchi B, Nishi S, Kondo D, Kaneko Y, Matsuki A, Imai N, Ueno M, Iguchi S, Sakatsume M, Narita I, Yamamoto T, Gejyo F. Osteopontin expression in acute renal allograft rejection. Kidney Int. 2005 Mar; 67(3): 886-96. (Pubitemid 41623313)
26. Atkins R, Nikolic-Paterson D, Song Q, Lan H. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol. 1996 Nov; 7(11): 2271-8. (Pubitemid 27465931)
27. Galla J. IgA nephropathy. Kidney Int. 1995 Feb; 47(2): 377-87.
28. Thomas M, Harris K, Walls J, Furness P, Brunskill N. Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Renal Physiol. 2002 Oct; 283(4): F640-7. (Pubitemid 35033950)
29. Yard B, Chorianopoulos E, Herr D, van der Woude F. Regulation of endothelin-1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant. 2001 Sep; 16(9): 1769-75. (Pubitemid 32821407)